In the FIT-001 trial, the combination of darlifarnib and cabozantinib demonstrated promising early antitumor activity in patients with ccRCC who had previously progressed on cabozantinib.
Adanma Ayanambakkam, MD, MS
Advertisement
Ayanambakkam is an assistant professor of hematology oncology and an adjunct assistant professor of urology, associate program director of the OUHSC Hematology Oncology Fellowship Program, medical director of the Genitourinary Medical Oncology Research & SCC Infusion Center at Stephenson Cancer Center, University of Oklahoma Health Sciences Center.
Articles by Adanma Ayanambakkam, MD, MS
Adanma Ayanambakkam, MD, MS, discusses the FIT-001 trial and early findings on the safety profile for darlifarnib plus cabozantinib in ccRCC.
Although the trial includes multiple tumor types, the presented data focus on RCC, predominantly clear cell disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
FDA approves tebipenem pivoxil for complicated urinary tract infections
4
Retrospective study suggests differences in OAB therapy persistence among older adults
5